Phase II study of cladribine, high-dose cytarabine and idarubicin in patients with relapsed acute myeloid leukemia.

Trial Profile

Phase II study of cladribine, high-dose cytarabine and idarubicin in patients with relapsed acute myeloid leukemia.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 19 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 19 Feb 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top